Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial

MASH-COVID study group

Research output: Contribution to journalArticlepeer-review

53 Scopus citations

Fingerprint

Dive into the research topics of 'Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial'. Together they form a unique fingerprint.

INIS

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science